Initially developed as a CCR5 antagonist to inhibit HIV-1 entry, TAK-779 also antagonizes CCR2 and CXCR3, demonstrating potential for treating a range of Th1 cell-mediated diseases such as rheumatoid arthritis and cancer (Nedjai et al., 2015). Here, CXCR3 is linked to cancer.